Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5‐year ideal response

Man‐Fung Yuen, Daniel Yee‐Tak Fong, Danny Ka‐Ho Wong, John Chi‐Hang Yuen, James Fung, Ching‐Lung Lai – 28 November 2007 – The best time and hepatitis B virus (HBV) DNA level during an early lamivudine treatment period for predicting the long‐term outcome are unknown. We aimed to determine the optimal time and HBV DNA level during an early treatment period for the prediction of the response after a 5‐year lamivudine treatment.

Delayed‐onset primary cytomegalovirus disease after liver transplantation

Supha K. Arthurs, Albert J. Eid, Rachel A. Pedersen, Ross A. Dierkhising, Walter K. Kremers, Robin Patel, Raymund R. Razonable – 28 November 2007 – Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV) donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the outcome of this strategy by determining the incidence, clinical features, and risk factors of CMV disease among CMV D+/R− liver transplant recipients who received antiviral prophylaxis.

The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation

Jennifer T. Wells, Adnan Said, Rashmi Agni, Santiago Tome, Sarah Hughes, Parul Dureja, Michael R. Lucey – 28 November 2007 – Patients with clinical acute alcoholic hepatitis (AAH) are not considered suitable candidates for orthotopic liver transplantation (OLT). The histological correlates of AAH are often seen in the explanted liver at the time of transplantation. The importance of these findings remains inconclusive regarding their role as a prognostic marker for patient or allograft health.

Subscribe to